Michael Ewers

Michael Ewers is a full Professor, and the Principal Investigator of Brain Imaging and Biomarker Research Group at the University Hospital Munich. Research Dr. Ewers focuses on the detection of brain changes that underlie or modulate the manifestation of dementia symptoms in Alzheimer’s disease. His research employs fMRI and DTI as sources of analysis, based of which the team can investigate for the first locus the protective mechanisms of the brain to the onset of cognitive impairment, and for the second locus, the development of markers for the early AD detection. Recently, Dr. Ewers with his group identified a highly connected hub in the frontal cortex as a key brain region underlying reserve capacity in AD. The team also found TREM2 as a biological marker for the onset of AD, by applying machine learning based analysis approaches; the microglia activity marker TREM2 was proved to have a protective role in AD, suggesting a potential therapeutic target.

Lab Information

University Hospital Munich

Research Area and Skills

Recognize this scientist’s Expertise for their contribution in your research

Markers of Alzheimer’s Disease 0 Reserve and Resilience in Alzheimer’s Disease 0 Machine Learning and AI modelling 0 TREM2-related Microglia Activation 0

More

  • Post
  • Publication
  • Plasmid
  • Following (0)
  • Follower (2)


This guy hasn’t posted anything yet.

Hot Posts for You

Neutralizing antibodies (NAbs) are critical human immune defense mechanisms against viral infections. NAbs can bind to sites on the virus and inhibit entry of that virus into the host. It is a key parameter to evaluate COVID-19 vaccine efficacy per Guidelines from Development and ...Learn More


This 3D animation shows you how DNA is copied in a cell. It shows how both strands of the DNA helix are unzipped and copied to produce two identical DNA molecules. TranscriptDNA is a molecule made up of two strands twisted around each other in a double helix shape. Each strand is ...Learn More


IntroductionA gleam of light finally shone down on the global crisis of the prolonged battle against COVID-19, giving people hopes of preventive care and treatment in the near future by monoclonal antibodies against SARS-CoV-2. As stated the news of NIH’s phase III clinical ...Learn More


"Those who do not know history are obliged to repeat it" This famous phrase that could be from any history teacher to his suspended students has been attributed to great figures in history such as Napoleon or the philosopher George Santayana. In a modern version of it we could say ...Learn More


In recent years there is an increasing number of cytotoxic chemotherapeutic compounds with the ability to rapidly kill dividing cancer cells in preference to non-dividing healthy cells. Nevertheless, the major drawback of chemotherapy is that, in addition to damaging the cancer ...Learn More


The coronavirus pandemic caught everyone unprepared. We had to deal with the fear of an unknown virus which can be lethal for some people. And the whole world just stopped in an attempt to prevent the virus spread.Suddenly we had to adapt to a new way of living, socially isolated ...Learn More


This is the first episode of MolecularCloud Pioneer Scientist interview series. In this interview, MolecularCloud talks with Prof. Shuo Huang from Nanjing University about the recent publications of Dr. Huang’s team and the future prospect of biological nanopore technology. The ...Learn More


The increasing number of confirmed COVID-19 cases is prompting an unprecedented global effort to find a treatment for the disease. Given the fact that a new drug development could be a decade work from initial discovery to the marketplace, scientists are racing to search a cure ...Learn More


The previous article on precision medicine was focused on Pharmacogenomics as a fundamental aspect of cancer therapeutics. In this sequel, emphasis would be on the role of immuno-oncology in personalization of cancer therapy, citing anti PD therapy as an example with hypothetical ...Learn More


  1. Caballero MÁA, Song Z, Rubinski A, Duering M, Dichgans M, Park DC, Ewers M. Age-dependent amyloid deposition is associated with white matter alterations in cognitively normal adults during the adult life span. Alzheimers Dement. 2020 Mar 8. Epub ahead of print.

  2. Franzmeier N, Koutsouleris N, Benzinger T, Goate A, Karch CM, Fagan AM, McDade E, Duering M, Dichgans M, Levin J, Gordon BA, Lim YY, Masters CL, Rossor M, Fox NC, O'Connor A, Chhatwal J, Salloway S, Danek A, Hassenstab J, Schofield PR, Morris JC, Bateman RJ; Alzheimer's disease neuroimaging initiative (ADNI); Dominantly Inherited Alzheimer Network (DIAN), Ewers M. Predicting sporadic Alzheimer's disease progression via inherited Alzheimer's disease-informed machine-learning. Alzheimers Dement. 2020 Feb 11. [Epub ahead of print]

  3. Franzmeier N, Neitzel J, Rubinski A, Smith R, Strandberg O, Ossenkoppele R, Hansson O, Ewers M; Alzheimer’s Disease Neuroimaging Initiative (ADNI). Functional brain architecture is associated with the rate of tau accumulation in Alzheimer's disease. Nat Commun. 2020 Jan 17;11(1):347.


This guy hasn’t plasmids anything yet.

Hot plasmids


This guy has no following anyone.

Popular Cloud Scientists

Cloud Scientists

About Us · User Accounts and Benefits · Privacy Policy · Management Center · FAQs
© 2025 MolecularCloud